Search company, investor...

UBB - MetLife Life Insurance

Investors Count

3

Funding, Valuation & Revenue

3 Fundings

UBB - MetLife Life Insurance's latest funding round was a Acquired for on December 29, 2017.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

12/29/2017

Acquired

0

FY undefined

1

Corporate Majority

0

FY undefined

0

Corporate Minority

0

FY undefined

0

Date

12/29/2017

Round

Acquired

Corporate Majority

Corporate Minority

Amount

Investors

Valuation

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

0

0

This profile has not been claimed.

You're more than your latest funding, tell our customers your company's story.

UBB - MetLife Life Insurance Investors

3 Investors

UBB - MetLife Life Insurance has 3 investors. KBC Group invested in UBB - MetLife Life Insurance's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

12/29/2017

12/29/2017

1
Acquired

Bank

Belgium

United Bulgarian Bank

Subscribe to see more

Corporation

Bulgaria

MetLife

Subscribe to see more

Corporation

New York

First funding

12/29/2017

Last Funding

12/29/2017

Investor

United Bulgarian Bank

MetLife

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Board Seats

Type

Bank

Corporation

Corporation

Location

Belgium

Bulgaria

New York

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.